Global Carcinoid Syndrome Market Poised for Growth Through 2035 as Treatment Innovation and Diagnosis Rates Advance
Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Carcinoid Syndrome Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ResearchAndMarkets.com's offering.
The global carcinoid syndrome market is expected to record significant growth during the 2025–2035 forecast period, supported by the rising prevalence of neuroendocrine tumors, improved diagnostic capabilities and increasing demand for effective symptom management. Greater awareness among patients and healthcare professionals is contributing to higher diagnosis rates and broader adoption of approved carcinoid syndrome therapies.
Market expansion is also being supported by advances in targeted treatments and the availability of U.S. Food and Drug Administration-approved therapies. Somatostatin analogs, telotristat ethyl and peptide receptor radionuclide therapy remain important components of treatment strategies for eligible patients. Continued research and development activity is expected to expand the therapeutic pipeline, improve clinical outcomes and address unmet needs in advanced or difficult-to-manage cases.
Market Impact and Growth Outlook
North America holds the largest share of the global carcinoid syndrome market. The region benefits from advanced healthcare infrastructure, established neuroendocrine tumor treatment networks, strong awareness among clinicians and broad access to approved medicines. The United States remains a leading market for diagnosis and treatment, supported by specialist care, favorable research activity and access to therapies including somatostatin analogs and Xermelo.
Key Carcinoid Syndrome Market Drivers
Market Limitations
High treatment costs remain a major challenge for the global carcinoid syndrome market. Advanced therapies, including peptide receptor radionuclide therapy and long-term somatostatin analog treatment, can create substantial financial burdens for patients and healthcare systems. Access may be particularly limited in low- and middle-income countries where specialist services, reimbursement and diagnostic resources are less widely available.
Limited treatment options for advanced cases also represent an important market constraint. Although current therapies can support symptom control and disease management, variable treatment response and the need for sustained care continue to create unmet clinical demand. Addressing affordability, access and therapeutic durability will be critical to achieving broader market expansion.
Competitive Landscape
The global carcinoid syndrome market features established pharmaceutical companies and emerging biotechnology businesses focused on targeted therapies and improved symptom management. Competition is shaped by research and development investment, clinical trial results, regulatory approvals, product differentiation and the ability to demonstrate meaningful patient outcomes.
Prominent companies operating in the global carcinoid syndrome market include:
As diagnosis rates rise and the therapeutic pipeline evolves, market participants are expected to pursue clinical innovation, strategic partnerships and geographic expansion. These activities are likely to strengthen competition and support the continued development of the global carcinoid syndrome treatment market through 2035.
Research Methodology
1. Global Carcinoid Syndrome Market: Industry Outlook
1.1 Market Overview
1.2 Clinical Trials
1.3 Regulatory Landscape / Compliance
1.4 Key Trends
1.5 Market Dynamics
1.5.1 Impact Analysis
1.5.2 Market Drivers
1.5.3 Market Restraints
1.5.4 Market Opportunities
2. Global Carcinoid Syndrome Market (By Region), $Million, 2023-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Carcinoid Syndrome Market, by Country
2.1.2.1.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Carcinoid Syndrome Market, by Country
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Carcinoid Syndrome Market, by Country
2.3.2.1.1 Japan
3. Global Carcinoid Syndrome Market - Competitive Landscape and Company Profiles
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
3.2.1 Novartis AG
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Ipsen Pharma
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Lexicon Pharmaceuticals
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers/End Users
3.2.3.4 Analyst View
3.2.4 Crinetics
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers/End Users
3.2.4.4 Analyst View
3.2.5 Others
4. Research Methodology
List of Figures
Figure: Carcinoid Syndrome Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Carcinoid Syndrome Market, 2024 and 2035
Figure: Global Carcinoid Syndrome Market Key Trends, Impact Analysis, 2023-2035
Figure: North America Carcinoid Syndrome Market, $Million, 2023-2035
Figure: Europe Carcinoid Syndrome Market, $Million, 2023-2035
Figure: Asia-Pacific Carcinoid Syndrome Market, $Million, 2023-2035
List of Tables
Table: Market Snapshot
Table: Market Dynamics
Table: Global Carcinoid Syndrome Market (by Region), $Million, 2023-2035
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/1bx9a1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.